Mass General: Early Treatment With Lorlatinib Improves Survival and Prevents Disease Progression in Some Lung Cancer Patients
November 20, 2020
November 20, 2020
BOSTON, Massachusetts, Nov. 20 -- Massachusetts General Hospital issued the following news release:
Lung cancer patients with a specific genetic alteration lived longer and were protected against metastasis to the brain when treated early with the drug lorlatinib (Lorbrena), according to a study led by researchers at Massachusetts General Hospital (MGH), published in the New England Journal of Medicine (NEJM).
Non-small-cell lung cancer (NSCLC) accounts for 87% of all c . . .
Lung cancer patients with a specific genetic alteration lived longer and were protected against metastasis to the brain when treated early with the drug lorlatinib (Lorbrena), according to a study led by researchers at Massachusetts General Hospital (MGH), published in the New England Journal of Medicine (NEJM).
Non-small-cell lung cancer (NSCLC) accounts for 87% of all c . . .